A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS

NCT05569746 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Diarrhea-Associated Hemolytic Uremic Syndrome
Pediatric Kidney Disease
Hemolytic-Uremic Syndrome

Interventions

DRUG: INM004
OTHER: SoC

Sponsor

Inmunova S.A.

Collaborators

[object Object]
[object Object]
[object Object]